RETROPHIN, INC.
Biopharmaceutical Company
Reported lobbying by year
Filings
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Termination 3rd Quarter 2020
|
COVE STRATEGIES | $20,000 reported |
|
2nd Quarter - Report 2nd Quarter 2020
|
COVE STRATEGIES | $20,000 reported |
|
1st Quarter - Report 1st Quarter 2020
|
COVE STRATEGIES | $20,000 reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| COVE STRATEGIES | 7 | $140,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Pharmacy | PHA | 8 |
| Health Issues | HCR | 2 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
| Bill | Congress | Times named |
|---|---|---|
| S. 340 | 116th | 6 |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.